Additional information
| Active substance | Bremelanotide |
|---|---|
| Dosage | 0.5-1.5 mg/day |
| Water Retention | Minimal |
| Hepatotoxicity | No significant hepatotoxicity reported |
| Lab Test | Specific tests for PT 141 are not typically part of standard drug screenings |
| Also known as | Bremelanotide |
| Blood pressure | May cause transient increases in blood pressure |
| Trade name | Vyleesi |
| FORM | 1 vial x 2 mg |
| Storage conditions | Store at 2В°C to 8В°C (36В°F to 46В°F) |
| Chemical name | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH |
| Formula | C50H68N14O10 |
| Substance class | Peptide hormone |
| Main action | Melanocortin receptor agonist |
| Half-life | Approximately 2.7 hours |
| Dosage (medical) | 1.75 mg subcutaneously |
| Dosage (sports) | Not applicable |
| Effects | Increases sexual arousal and spontaneous erections |
| Side effects | Nausea, flushing, headache, hyperpigmentation, respiratory infections |
| Use in sports | Not typically used in sports |
| Manufacturer | Hubio Pharm |
|
Reviews
There are no reviews yet.